Product Description
PXL770 is a novel drug candidate that directly activates adenosine monophosphate-activated protein kinase (AMPK); Based on its central metabolic role, we believe that targeting AMPK offers the opportunity to pursue a wide range of indications to treat chronic metabolic diseases, including diseases that affect the liver, such as NASH and rare metabolic disorders (e.g. adrenoleukodystrophy). (Sourced from: https://www.poxelpharma.com/en_us/pipeline/nash)
Mechanisms of Action: AMPK Activator
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Fast Track - AdrenoleukodystrophyOrphan Drug - AdrenoleukodystrophyOrphan Drug - Kidney Diseases|Polycystic Kidney, Autosomal Dominant *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Poxel
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Adreno-myeloneuropathy|Adrenoleukodystrophy
Phase 1: Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| X-ALD or ALD | P2 |
Not yet recruiting |
Adrenoleukodystrophy|Adreno-myeloneuropathy |
2024-09-01 |
32% |
| START770 | P2 |
Active, not recruiting |
Adreno-myeloneuropathy |
2022-07-29 |
|
| PXL770-009 | P1 |
Completed |
Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Non-alcoholic Steatohepatitis |
2021-03-29 |
21% |